Idéal Investisseur Galteron Galteron
Français English
CAC 40 : Market closed
8 216,78 pts
-1.62%


Last updated : 17/11/2026 - 17h35
🏠 Home   ➤    Stock news

DBV Technologies shares fall 8.5% over the week, among the worst performers in the SBF 120

The Châtillon-based biotech closes the session near the bottom of the SBF 120, in a European market clearly trending downward. The stock extends its weekly decline while its US regulatory application continues to progress.


DBV Technologies shares fall 8.5% over the week, among the worst performers in the SBF 120

A sharper decline than the index, below the moving averages

The share of DBV Technologies falls 3.95% to €1.80, while the SBF 120 drops 1.56%. It ranks among the largest declines in the index, ahead of Inventiva and Nanobiotix among the most affected stocks.

The stock is below its 20-day moving average (MM20) at €1.84 (a gap of -2.28%) and below its 50-day moving average (MM50) at €1.90 (-5.37%), erasing during the session part of the rebound begun in early November. It is down 8.27% over the week but remains up 14.67% over one month.

The €1.57 support level is about 13% below the current price. Results for the last quarter also highlighted the fragility of its cash position: the group reported substantial doubt about its ability to continue as a going concern and a need for additional capital beyond the third quarter of 2027.

An FDA application under review and clinical data presented in the United States

The Viaskin Peanut patch is the subject of a Biologics License Application (BLA) for children aged 4 to 7, with priority review requested and an FDA decision expected in the fourth quarter of 2026, according to results published on October 28. The group plans a second filing, for children aged 1 to 3, in 2027.

On November 13, new analyses of the VITESSE study were presented at the ACAAI congress in Phoenix. They concern the severity of allergic reactions under treatment. The stock trades about 36% below its 200-day moving average (MM200) of €2.81, after a 24% decline over three months.

The next items to watch are the FDA decision expected by year-end and the company's financing needs.

Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning ✓ Euronext data ✓ AI-powered analysis


Sector Pharmacie et biotechnologies › Biotechnologies


Context

Period
  • Period: 9M 2026
Key reported figures
  • Revenue: 3,1 millions de dollars
  • Quarterly revenue: 3,1 millions de dollars
  • Revenue growth: -38 %
  • Net income: -162,5 millions de dollars
  • Free cash flow: -159,4 millions de dollars
Risks mentioned
  • Substantial doubt exists about the Company's ability to continue as a going concern within twelve months
  • Manufacturing remediation activities ongoing at Fareva following FDA Warning Letter of April 2026
  • Company requires additional capital to fund operations beyond Q3 2027
Opportunities identified
  • BLA for VIASKIN Peanut Patch in children aged 4-7 years submitted with Priority Review requested, expected FDA determination in Q4 2026
  • Planned BLA submission for toddlers aged 1-3 years in 2027 with potential rolling submission approach
  • Recent $50 million ADS financing completed and $150 million ATM program refreshed to support operations and commercial readiness

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Advertisement
Every morning
Technical market signals,
before the opening bell.
CAC 40 · SBF 120 · Signals · Analysts
🤖
Today's edition — pre-market
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Bullish signals
+5,2%
+1,8%
+0,9%
📉 Bearish signals
-14%
-5,7%
🔄 Analyst opinions
▲ 35 €
▼ 80 €
Sign up to see everything →
Before 9 AM every morning
Euronext data
AI-powered analysis





BOURSE · Chaque matin
La synthèse bourse,
avant l'ouverture.
Notre moteur analyse chaque nuit le CAC 40 et le SBF 120. Ce qui mérite attention remonte directement dans votre boîte mail. Gratuit.
✓ Avant 9h00 ✓ 1000+ inscrits ✓ 100% gratuit
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours sur les valeurs Euronext, chaque matin avant 9h.
tendance · 6 séances
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours